Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis

被引：0

作者：

Fox, E. ^{[1
]}

Steinman, L. ^{[2
]}

Hartung, H. ^{[3
,4
,5
,6
]}

Alvarez, E. ^{[7
]}

Qian, P. ^{[8
]}

Wray, S. ^{[9
]}

Robertson, D. ^{[10
]}

Huang, D. ^{[11
]}

Selmaj, K. ^{[12
]}

Wynn, D. ^{[13
]}

Weiss, M. S. ^{[14
]}

Bosco, J. A. ^{[14
]}

Power, S. A. ^{[14
]}

Mok, K. A. ^{[14
]}

Lee, L. ^{[14
]}

Cree, B. A. ^{[15
]}

机构：

[1] Cent Texas Neurol Consultants, Round Rock, TX USA

[2] Stanford Univ, Stanford, CA 94305 USA

[3] Heinrich Heine Univ, Dusseldorf, Germany

[4] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[5] Med Univ Vienna, Vienna, Austria

[6] Palacky Univ, Olomouc, Czech Republic

[7] Univ Colorado, Aurora, CO USA

[8] Swedish Med Ctr, Seattle, WA USA

[9] Hope Neurol, Knoxville, TN USA

[10] Univ S Florida, Tampa, FL 33620 USA

[11] Mt Carmel Hlth Syst, Ctr Multiple Sclerosis, Westerville, OH USA

[12] Univ Warmia & Mazury, Ctr Neurol, Lodz, Poland

[13] Consultants Neurol, Northbrook, IL USA

[14] TG Therapeut Inc, New York, NY USA

[15] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P105

引用

页码：68 / 68

页数：1

共 50 条

[21] Monoclonal antibody therapy for B-Cell lymphoma: Clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan
Tobinai, K
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (05) : 411 - 419
[22] Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan
Kensei Tobinai
International Journal of Hematology, 2002, 76 : 411 - 419
[23] Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets
Lovett-Racke, A.
Liu, Y.
Gormley, M.
Wray, S.
Racke, M.
Shubin, R.
Su, W.
Eubanks, J.
Fox, E.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 609 - 610
[24] Anti-CD20 monoclonal antibody as a new treatment modality for B-cell lymphoma
Hotta, T
ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (04) : 275 - 279
[25] Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Multiple Sclerosis: A Review of Clinical Considerations
William T. Barham
Kathryn M. Dillman
Joseph D. Hebert
Christian K. Kerut
Rachel J. Klapper
Shahab Ahmadzadeh
Sahar Shekoohi
Elyse M. Cornett
Alan D. Kaye
SN Comprehensive Clinical Medicine, 6 (1)
[26] Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review
Brown, Justin D.
Muston, Benjamin T.
Massey, Jennifer
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 86
[27] Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody
Abou Mourad, Y
Taber, A
Chehal, A
Shamseddine, A
ANNALS OF HEMATOLOGY, 2004, 83 (05) : 319 - 321
[28] Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody
Yasser Abou Mourad
Ali Taher
Aref Chehal
Ali Shamseddine
Annals of Hematology, 2004, 83 : 319 - 321
[29] The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
Cooper, N
Stasi, R
Cunningham-Rundles, SS
Feuerstein, MA
Leonard, JP
Amadori, S
Bussel, JB
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) : 232 - 239
[30] B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Leandro, Maria J.
ARTHRITIS RESEARCH & THERAPY, 2013, 15

← 1 2 3 4 5 →